


## hBChE-IN-1

<b>Cat. No.:</b>	HY-149273
<b>CAS No.:</b>	1776948-12-9
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>34</sub> N <sub>2</sub> OS <sub>2</sub>
<b>Molecular Weight:</b>	466.7
<b>Target:</b>	Cholinesterase (ChE); Amyloid-β; Tau Protein
<b>Pathway:</b>	Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	hBChE-IN-1 (compound 4), a quinolizidinyll derivative, is a potent hBChE inhibitor (IC <sub>50</sub> =7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ <sub>40</sub> protein aggregation, with IC <sub>50</sub> values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	hBCHE 0.0070 ± 0 μM (IC <sub>50</sub> )	equine serum BChE 0.088 μM (IC <sub>50</sub> )	EeAChE 0.18 μM (IC <sub>50</sub> )	hAChE 7.84 ± 0.8 μM (IC <sub>50</sub> )

### REFERENCES

[1]. Tonelli M, et al. Thioxanthone-based derivatives as multitarget therapeutic leads for Alzheimer's disease. Eur J Med Chem. 2023 Mar 15;250:115169.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA